Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Septerna, Inc. (NASDAQ:SEPN) has received an average recommendation of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $43.1250.

A number of brokerages have issued reports on SEPN. Truist Financial upped their target price on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. JPMorgan Chase & Co. upped their target price on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus began coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company.

Septerna Stock Performance

SEPN stock opened at $31.15 on Monday. Septerna has a one year low of $9.85 and a one year high of $32.63. The firm has a market capitalization of $1.40 billion, a PE ratio of -38.46 and a beta of 2.39. The firm has a 50-day moving average of $26.15 and a two-hundred day moving average of $26.50.

Septerna (NASDAQ:SEPN) last issued its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. On average, equities research analysts anticipate that Septerna will post -1.57 earnings per share for the current year.

Insider Activity at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samira Shaikhly sold 5,935 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $28.93, for a total value of $171,699.55. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,941.49. This trade represents a 88.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 21,733 shares of company stock valued at $623,707 over the last three months. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Septerna

Several institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG increased its stake in shares of Septerna by 5.3% in the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after buying an additional 744 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Septerna in the fourth quarter valued at $35,000. JPMorgan Chase & Co. increased its stake in shares of Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares in the last quarter. PharVision Advisers LLC increased its stake in shares of Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after buying an additional 1,780 shares in the last quarter. Finally, Nuveen LLC increased its position in Septerna by 7.7% in the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after purchasing an additional 1,837 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.